SQZ Biotechnologies Company (SQZ) Stock Analysis
DELISTED 2023
What happened to SQZ Biotechnologies Company (SQZ) stock?
SQZ Biotechnologies Company (SQZ) no longer trades on public markets. It was delisted in July 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SQZ Biotechnologies Company (SQZ) trades at $0.435. SQZ Biotechnologies is a clinical-stage biotechnology firm specializing in cell therapies for cancer, autoimmune, and infectious diseases. Market cap: $12.8M, Sector: Healthcare.
Last analyzed: May 7, 2026Analyst Coverage for SQZ: SQZ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SQZ against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
SQZ: 2/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →SQZ Biotechnologies Company (SQZ) Healthcare & Pipeline Overview
SQZ Biotechnologies Company focuses on developing cell therapies using its proprietary SQZ platform, targeting cancer, autoimmune, and infectious diseases. The company's lead candidate, SQZ-PBMC-HPV, is in Phase I clinical trials, positioning SQZ in the competitive biotechnology landscape with a focus on innovative cell-based treatments.
What Is the Investment Thesis for SQZ?
SQZ Biotechnologies presents a high-risk, high-reward investment profile characteristic of clinical-stage biotech firms. The company's proprietary SQZ platform offers a novel approach to cell therapy, potentially disrupting traditional treatment paradigms. The primary value driver is the successful advancement of SQZ-PBMC-HPV and SQZ-AAC-HPV through clinical trials, with Phase I data readouts being critical milestones. Positive data could lead to significant market valuation increases, while setbacks could negatively impact the stock. The company's current market capitalization of $12.8M reflects the early stage of its clinical programs and inherent risks. Investors should closely monitor clinical trial results, regulatory developments, and the company's cash runway, as these factors will heavily influence SQZ's future prospects.
Based on FMP financials and quantitative analysis
SQZ Key Highlights
SQZ-PBMC-HPV is in Phase I clinical trials as a monotherapy and in combination with other immuno-oncology agents.
- SQZ-AAC-HPV is in Phase I clinical trials for the treatment of HPV16+ advanced or metastatic solid tumors.
- Gross Margin stands at 46.6%, indicating potential for profitability as clinical programs advance.
- The company's Beta is 2.71, suggesting high volatility relative to the market.
- SQZ Biotechnologies has no dividend yield, typical for a clinical-stage biotechnology company focused on reinvesting earnings into research and development.
Who Are SQZ's Competitors?
SQZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.7M | 67 |
| CRSP CRISPR Therapeutics AG | $58.90 | -1.52% | $5.68B | 44 |
| EDIT Editas Medicine, Inc. | $2.94 | -9.54% | $451M | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SQZ's Key Strengths?
Proprietary SQZ platform technology.
- Diverse pipeline of cell therapy candidates.
- Focus on unmet medical needs.
- Experienced management team.
What Are SQZ's Weaknesses?
Early-stage clinical development.
- Limited financial resources.
- Dependence on clinical trial outcomes.
- High cash burn rate.
What Could Drive SQZ Stock Higher?
Data readouts from Phase I clinical trials of SQZ-PBMC-HPV for HPV16+ solid tumors.
- Data readouts from Phase I clinical trials of SQZ-AAC-HPV for HPV16+ solid tumors.
- Advancement of SQZ Activating Antigen Carriers into preclinical development.
- Advancement of SQZ Tolerizing Antigen Carriers into preclinical development.
What Are the Key Risks for SQZ?
Financial-distress signal — its Altman Z-Score of -22.95 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-86.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for SQZ-PBMC-HPV and SQZ-AAC-HPV.
- Regulatory delays or non-approval of SQZ's cell therapies.
- Competition from established biotechnology and pharmaceutical companies.
- Dependence on securing additional funding to support clinical development.
- Intellectual property challenges or infringement.
What Are the Growth Opportunities for SQZ?
- Expansion of SQZ-PBMC-HPV into Additional HPV-Related Cancers: SQZ has the opportunity to expand the application of SQZ-PBMC-HPV beyond its current focus on HPV16+ tumors to other HPV-related cancers. This expansion could significantly increase the addressable patient population and market potential. Success in current trials could pave the way for trials in other HPV-driven malignancies, potentially capturing a larger share of the oncology market. This strategy leverages the existing platform and clinical data to broaden the therapeutic reach of SQZ-PBMC-HPV.
- Development of SQZ Activating Antigen Carriers for Infectious Diseases: SQZ's Activating Antigen Carriers platform holds potential for developing novel vaccines and immunotherapies for infectious diseases. With the ongoing global threat of emerging and drug-resistant infections, there is a significant market opportunity for innovative approaches to disease prevention and treatment. The company could partner with pharmaceutical companies or government agencies to accelerate the development and commercialization of these therapies, addressing a critical public health need.
- Advancement of SQZ Tolerizing Antigen Carriers for Autoimmune Disorders: The SQZ Tolerizing Antigen Carriers platform offers a potential solution for autoimmune disorders by inducing immune tolerance to specific antigens. This approach could lead to the development of disease-modifying therapies for conditions like rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. The autoimmune disease market is substantial, and effective tolerizing therapies could capture a significant share. SQZ could focus on specific autoimmune indications with high unmet needs and limited treatment options.
- Strategic Partnerships with Pharmaceutical Companies: SQZ can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its cell therapies. These partnerships could provide access to funding, expertise, and resources needed to advance clinical trials and navigate regulatory pathways. Collaborations could also involve co-development agreements, licensing deals, or joint ventures, allowing SQZ to share the risks and rewards of its innovative technologies. Successful partnerships could validate the SQZ platform and enhance its credibility in the industry.
- Expansion into New Geographic Markets: SQZ has the opportunity to expand its clinical trials and commercial operations into new geographic markets, particularly in Europe and Asia. These regions have large patient populations and growing healthcare markets, offering significant potential for growth. The company could establish collaborations with local research institutions and hospitals to conduct clinical trials and build a presence in these markets. International expansion could diversify SQZ's revenue streams and reduce its reliance on the US market.
What Opportunities Does SQZ Have?
- Strategic partnerships with pharmaceutical companies.
- Expansion into new therapeutic areas.
- Positive clinical trial results.
- Advancements in cell therapy technology.
What Are SQZ's Competitive Advantages?
- Proprietary SQZ platform technology.
- Early-stage clinical pipeline.
- Intellectual property protection.
- Expertise in cell therapy engineering.
What Does SQZ Do?
SQZ Biotechnologies Company, founded in 2013 and headquartered in Watertown, Massachusetts, is a clinical-stage biotechnology company dedicated to creating transformative cell therapies. The company's core technology, the SQZ platform, enables the engineering of a patient's own cells to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. SQZ's lead product candidate, SQZ-PBMC-HPV, is derived from the SQZ Antigen Presenting Cells (APC) platform and is currently in a Phase I clinical trial. This trial evaluates the safety and efficacy of SQZ-PBMC-HPV as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, such as cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. In addition to SQZ-PBMC-HPV, the company is also developing SQZ-AAC-HPV, which is also in a Phase I clinical trial for treating HPV16+ advanced or metastatic solid tumors, both as a standalone treatment and in combination with other immune-oncology therapies. SQZ's pipeline also includes the SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers platforms, which are designed to address a broader range of diseases by either activating or suppressing the immune system. SQZ Biotechnologies is focused on advancing its innovative cell therapy platforms through clinical development to address unmet medical needs in various therapeutic areas. The company operates primarily in the United States, focusing on research, development, and clinical trials.
What Products and Services Does SQZ Offer?
- Develops cell therapies for cancer.
- Creates treatments for autoimmune diseases.
- Engineers cell therapies for infectious diseases.
- Utilizes the SQZ Antigen Presenting Cells platform.
- Conducts Phase I clinical trials for SQZ-PBMC-HPV.
- Develops SQZ Activating Antigen Carriers.
- Develops SQZ Tolerizing Antigen Carriers.
How Does SQZ Make Money?
- Develops proprietary cell therapy platforms.
- Out-licenses or co-develops therapies with pharmaceutical partners.
- Generates revenue through research grants and collaborations.
- Aims to commercialize cell therapy products upon regulatory approval.
What Industry Does SQZ Operate In?
SQZ Biotechnologies operates within the competitive and rapidly evolving biotechnology industry, specifically in the cell therapy segment. This sector is characterized by high growth potential, driven by advancements in immunotherapy and personalized medicine. Companies like SQZ are striving to develop innovative treatments for diseases with unmet medical needs, particularly in oncology and autoimmune disorders. The industry is marked by intense competition, stringent regulatory requirements, and significant investment in research and development. Success depends on clinical trial outcomes, regulatory approvals, and the ability to secure funding.
Who Are SQZ's Key Customers?
- Patients with cancer.
- Patients with autoimmune diseases.
- Patients with infectious diseases.
- Pharmaceutical companies (potential partners).
- Research institutions (collaborators).
Company Profile
SQZ Biotechnologies Company operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Howard Bernstein. SQZ has traded publicly since 2020.
Financial Health
SQZ Biotechnologies Company's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -22.95 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for SQZ Biotechnologies Company stands at -86.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -78.3%, showing how much profit it generates from its asset base. A current ratio of 3.12 indicates the company holds enough short-term assets to cover its near-term obligations.
SQZ Valuation & Market Position
With a $12.8M market cap, SQZ Biotechnologies Company sits in the micro-cap segment of the market.
SQZ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary SQZ platform technology.
- Diverse pipeline of cell therapy candidates.
- Focus on unmet medical needs.
- Experienced management team.
Bear Case
- Early-stage clinical development.
- Limited financial resources.
- Dependence on clinical trial outcomes.
- High cash burn rate.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SQZ Latest News
No recent news available for SQZ.
Leadership: Howard Bernstein
CEO
Howard Bernstein serves as the CEO of SQZ Biotechnologies Company. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions in various companies, focusing on strategic development, commercialization, and financial management. Bernstein's expertise spans across multiple therapeutic areas, including oncology and immunology. His experience in navigating complex regulatory landscapes and building successful biotechnology ventures makes him well-suited to lead SQZ Biotechnologies through its clinical development and commercialization efforts. He is responsible for overseeing the company's overall strategy, operations, and financial performance.
Track Record: Under Howard Bernstein's leadership, SQZ Biotechnologies has advanced its lead product candidates, SQZ-PBMC-HPV and SQZ-AAC-HPV, into Phase I clinical trials. He has focused on securing strategic partnerships and funding to support the company's research and development programs. Bernstein has also overseen the expansion of SQZ's pipeline and the development of its proprietary SQZ platform. His strategic decisions have been instrumental in positioning SQZ Biotechnologies as a key player in the cell therapy field.
SQZ Healthcare Stock FAQ
What happened to SQZ Biotechnologies Company (SQZ) stock?
SQZ Biotechnologies Company (SQZ) no longer trades on public markets. It was delisted in July 2023. The figures below are historical and are not a current quote.
Can I still buy SQZ shares?
No. SQZ stopped trading on public markets in July 2023, so the shares are not available through a broker. Anything you see quoted for SQZ elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SQZ stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to SQZ Biotechnologies Company. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does SQZ Biotechnologies Company do?
SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on developing cell therapies for patients with cancer, autoimmune, and infectious diseases. The company's proprietary SQZ platform enables the engineering of a patient's own cells to deliver therapeutic payloads directly into target cells.
What do analysts say about SQZ stock?
Analyst coverage of SQZ Biotechnologies is limited, reflecting the company's early stage of development and small market capitalization. Existing reports focus on the potential of the SQZ platform and the clinical progress of its lead candidates. Valuation metrics are highly dependent on clinical trial outcomes and regulatory milestones.
What are the main risks for SQZ?
The primary risks for SQZ Biotechnologies include clinical trial failures, regulatory hurdles, and competition from established biotechnology companies. Clinical trial failures could significantly impact the company's valuation and future prospects. Regulatory delays or non-approval of its cell therapies could also hinder its commercialization efforts. SQZ faces competition from larger companies with more resources and established market positions.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.